# Terminal Repeats Impact Collagen Triple-Helix Stability through Hydrogen Bonding 

 Yang Li ${ }^{\dagger}$ *
${ }^{\dagger}$ Guangdong Provincial Key Laboratory of Biomedical Imaging and Guangdong Provincial Engineering Research Center of Molecular Imaging, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai 519000, China
${ }^{\ddagger}$ Cardiac Surgery and Structural Heart Disease Unit of Cardiovascular Center, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai 519000, China
${ }^{\text {s }}$ Department of Radiology, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai 519000, China
${ }^{\wedge}$ Department of Biomedical Engineering, University of Utah, Salt Lake City, Utah 84112, USA
\|Department of Civil \& Environmental Engineering, College of Engineering \& Computer Science, Syracuse University, Syracuse, New York 13244, USA
*Correspondence to:
Gang Li: gangli73@163.com; Zhao Qin: zqin02@syr.edu; Yang Li: liyang266@ mail.sysu.edu.cn

## Table of Contents

|  | Page |
| :---: | :---: |
| Section 1: Materials and Methods | 2 |
| Materials | 2 |
| Solid-phase peptide synthesis | 3 |
| Cleavage protocols | 3 |
| Purification and mass spectrometry | 4 |
| Circular dichroism spectroscopy | 4 |
| B-factor analysis | 5 |
| Fully atomistic molecular dynamics of collagen sequences | 5 |
| Post analysis of simulation results | 6 |
| Differential scanning calorimetry | 6 |
| Gelatin binding assay | 7 |
| Immunofluorescence staining | 7 |
| Section 2: Supplementary Tables and Figures | 8 |
| Table S1. Terminal sequences of human collagen triple-helix regions. | 8 |
| Table S2. Sequences of all CMPs and their $T_{\mathrm{m}}$ values. | 9 |
| Table S3. Crystal structure analysis of CMP triple-helices in PDB. | 10 |
| Table S4. Comparison between various $T_{\mathrm{m}}$ values of similar CMPs. | 11 |
| Figure S1. $T_{\mathrm{m}}$ values of $\mathrm{Ac}-(\mathrm{GPO})_{7}-\mathrm{NH}_{2}$ under different CD heating rates. | 12 |
| Figure S2. The $T_{\mathrm{m}}$ values of (POG) ${ }_{\mathrm{n}}$ and (GPO) $)_{\mathrm{n}}(\mathrm{n}=5 \sim 9)$. | 13 |
| Figure S3-4. Normalized B-factors of CMP peptide chains in PDB. | 14-15 |
| Figure S5. The B-factor deviation at N-terminus of CMP triple-helices in PDB. | 16 |
| Figure S6-7. Molecular dynamics simulation of CMP 1, 2, 3, and 2E. | 17-18 |
| Figure S8. Experimental curves of the DSC. | 19 |
| Figure $\mathrm{S} 9-10 . T_{\mathrm{m}}$ value changes with stepwise residue incorporations at N - and C-termini. | 20-21 |
| Figure S11. CMP and anti-collagen I antibody staining of rat heart tissue. | 22 |
| Figure S12. $\Phi, \psi$ angles of representitive residues in simulated structures of CMP 2 and $\mathbf{3}$. | 23 |
| Section 3: MALDI and CD characterization of all CMPs | 24-52 |
| References | 52 |

## Section 1: Materials and Methods

## Materials

Commercially available materials and reagents were used without further purification. The solvents, resin, Fmoc amino acids, and reagents used in the synthesis and purification of the peptides were purchased from the following suppliers.

| General reagent | Supplier | Catalog number |
| :---: | :---: | :---: |
| $N$-Methylpyrrolidinone (NMP) | Aladdin | M100588-2.5L |
| $N, N$-Dimethylformamide (DMF) | Aladdin | D112002-500ml |
| Dimethyl sulfoxide (DMSO) | Aladdin | D106264-50g |
| Methylene Chloride (DCM) | Aladdin | D116146-4L |
| Acetonitrile | Macklin | A800362-4L |
| Ethyl ether | Guangzhou chemical reagent factory | 2020120510 |
| TentaGel RAM resin | Peptides International | RTS-9995-PI |
| Fmoc-Pro-Wang resin | Aladdin | P118261-5g |
| Fmoc-Gly-Wang resin | Aladdin | G116094-5g |
| Fmoc-Hyp-Wang resin | GL Biochem | 41506 |
| Fmoc-Gly-OH | EMD Millipore | 852001 |
| Fmoc-Pro-OH | EMD Millipore | 852017 |
| Fmoc-Hyp(tBu)-OH | EMD Millipore | 852036 |
| Fmoc-Sar-OH | Macklin | F809960-25g |
| Methyl iodide | Anaiji | W6107051000-A01 |
| Piperidine | Detian Fine Chemicals | 20191105 |
| O-(7-Azabenzotriazol-1-yl)- $N, N, N^{\prime}, N^{\prime}-$ tetramethyluronium hexafluorophosphate (HATU) | Aladdin | H109327-100g |
| 1-Hydroxy-7-azabenzotriazole (HOAt) | Macklin | H811122-100g |
| (7-Azabenzotriazol-1-yloxy) trispyrrolidinophosphonium hexafluorophosphate (PyAOP) | GL Biochem | GLS190801-00809 |
| $N$-Ethyldiisopropylamine (DIPEA) | EMD Millipore | S1807494945 |
| Acetic acid | Aladdin | A116174-500ml |
| Trifluoroacetic acid (TFA) | Macklin | T818782-500ml |
| Triisopropylsilane (TIS) | Macklin | T819181-100ml |
| 5(6)-Carboxyfluorescein | Macklin | C804899-1g |
| Anhydrous potassium carbonate | Aladdin | P111561-100g |

## Solid-phase peptide synthesis

Peptides were prepared using TentaGel R RAM resin (substitution level: $0.19 \mathrm{mmol} / \mathrm{g}$ ) to give C-terminal amidation via solid-phase synthesis by manual or automated peptide synthesizer (Gyros Protein Technologies, PurePep Chorus). For manual synthesis, each peptide was typically synthesized on 50 mg of resin (containing $10 \mu \mathrm{~mol}$ of reaction sites) swollen in 0.4 mL of DMF for over 1 hour before deprotection and the first coupling step. For coupling, the resin was agitated with a solution of Fmoc amino acids ( $50 \mu \mathrm{~mol}$ ), HATU ( $50 \mu \mathrm{~mol}, 19 \mathrm{mg}$ ), HOAt ( $50 \mu \mathrm{~mol}, 6.8 \mathrm{mg}$ ), and DIPEA ( $75 \mu \mathrm{~mol}, 13 \mu \mathrm{~L}$ ) in 0.4 mL DMF over a three-hour period. The Fmoc protection group was removed by incubating the resin in DMF for 20 minutes with $20 \% \mathrm{v} / \mathrm{v}$ piperidine. The resin was drained and cleaned after each reaction. Following each reaction, the resin was drained and washed with DMF ( $3 \times 10 \mathrm{~mL}$ ). The N-terminal amine of each sequence was acetylated by combining the resin ( $5 \mu \mathrm{~mol}$ ) with a solution of acetic acid ( $50 \mu \mathrm{~mol}, 3 \mu \mathrm{~L}$ ), HOAt ( $50 \mu \mathrm{~mol}, 6.8 \mathrm{mg}$ ), HATU ( $50 \mu \mathrm{~mol}, 19 \mathrm{mg}$ ), and DIPEA ( $75 \mu \mathrm{~mol}, 13 \mu \mathrm{~L}$ ) in 0.5 mL of DMF at room temperature for 3 hours after Fmoc-deprotection of the final amino residue. The standard Kaiser and chloranil resin tests were used to monitor all coupling and deprotection reactions. The chemical reagents and the ratios used for the automated systhesis were the same as the manual synthesis. Each amino acid was double coupled under heating at $50^{\circ} \mathrm{C}$ for 5 min and the Fmoc protection group was removed with two rounds of 90 s treatment of $20 \%$ piperidine.

Fmoc-Gly-Wang resin (substitution level: $0.40 \mathrm{mmol} / \mathrm{g}$ ) pre-coupled with Gly was used to produce the C-terminal carboxyl peptide $\mathrm{Ac}-(\mathrm{POG})_{7}-\mathrm{OH} . \mathrm{Ac}-(\mathrm{GPO})_{7}-\mathrm{OH}$ and $\mathrm{Ac}-(\mathrm{OGP})_{7}-\mathrm{OH}$ were purchased from GL Biochem (Shanghai). The peptide containing the C-terminal methyl ester was prepared by reacting the C-terminal carboxyl peptide Ac-(GPO) $)_{7}-\mathrm{OH}(2.5 \mu \mathrm{~mol}, 5 \mathrm{mg})$ with potassium carbonate ( $7.8 \mu \mathrm{~mol}, 1.1 \mathrm{mg}$ ) and methyl iodide ( 5.2 $\mu \mathrm{mol}, 0.32 \mu \mathrm{~L}$ ) in 1 mL DMF. The reaction mixture was stirred for 24 hours at room temperature. After the reaction, insoluble potassium carbonate was removed by filtration and the peptide product was purified by HPLC.


## Cleavage protocols

Before cleavage of the polypeptide, the resin was washed and drained with DMF ( $3 \times 10 \mathrm{~mL}$ ) and DCM ( $5 \times 10 \mathrm{~mL}$ ). Typically, RAM resin ( $5 \mu \mathrm{~mol}$ ) was treated with 1 mL mixture of TFA/TIS/water (95:2.5:2.5) with stirring for over 3 hours. After that, the resin was rinsed with 0.5 mL of TFA. The TFA cleavage solution was collected and evaporated under a stream of nitrogen down to roughly 0.5 mL after the resin was filtered. Then the crude peptide was precipitated in 5 mL of cold diethyl ether. The crude product was rinsed twice with cold diethyl ether after
centrifugation. Wang resin was treated the same as RAM resin, except that the cleavage fluid was a mixture of TFA and DCM (50:50).

## Purification and mass spectrometry

Using a mixture of water (A) and acetonitrile (B) containing $0.1 \%$ TFA, all peptides were purified using reversephase high performance liquid chromatography (HPLC) on a semi-preparative column (Agilent ZORBAX StableBond 300 C 18 ) at a linear gradient: $5 \%$ to $45 \%$ acetonitrile for 30 min . For semi-preparative HPLC, flow rates of $4 \mathrm{~mL} / \mathrm{min}$ were employed. The pure fractions were collected and lyophilized.

| Time (min) | 0 | 5 | 25 | 25.5 | 30 |
| :---: | :---: | :---: | :---: | :---: | :---: |
| B\% | $5 \%$ | $5 \%$ | $45 \%$ | $5 \%$ | $5 \%$ |

Mass spectrometry was used to verify all purified peptides. A Shimadzu 8020 or a Bruker Reflex III matrix aided laser analytical ionization-time of flight (MALDI/TOF) mass spectrometer were used to collect mass spectra. The lyophilized products were dissolved in Milli-Q water as stock solutions. The UV absorbance of the CMP solutions was measured at 214 nm for unlabeled peptides (extinction coefficient: $2200 \mathrm{M}^{-1} \mathrm{~cm}^{-1}$ per peptide bond) and 492 nm for the carboxyfluorescein-tagged CMPs (extinction coefficient: $70000 \mathrm{M}^{-1} \mathrm{~cm}^{-1}$ per tag) on a IMPLEN NP80 Nano drop using a quartz cell with a 1 cm cell path length. ${ }^{1}$

## Circular dichroism (CD) spectroscopy

CMP stock solutions were diluted to $150 \mu \mathrm{M}$ in $1 \times \mathrm{PBS}$ and heated at $80^{\circ} \mathrm{C}$ for 10 min before incubation at $4^{\circ} \mathrm{C}$ for over 48 hours to allow the peptide strands to fully assemble into the triple-helix. Peptides containing an N terminal amino group were also diluted in NaOH solutions ( $3.5 \mathrm{mM}, \mathrm{pH} 11.5$ ) to a final peptide concentration of $150 \mu \mathrm{M}$. On a JASCO J-1500 CD spectrophotometer, CD measurements of the peptide solutions were taken in quartz cells with a path length of 0.1 cm .

The CD spectra were scanned with the parameters (scanning speed: $20 \mathrm{~nm} / \mathrm{min}$; data pitch: 0.1 nm ; bandwidth: 5 nm ; digital integration time: 16 s ). The thermal denaturation curves were obtained by monitoring the ellipticity at 225 nm with a heating rate of $0.5^{\circ} \mathrm{C} / \mathrm{min}$ from 4 to $80^{\circ} \mathrm{C}$. Using the JASCO Spectra Manager software (Version 2.10.05), a melting curve's derivative was constructed, and the temperature at the lowest of the derivative curve was defined as the melting temperature $\left(T_{\mathrm{m}}\right)$. For all collagen mimetic peptides, the difference between the two recorded $T_{\mathrm{m}}$ values was less than $1^{\circ} \mathrm{C}$, and each $T_{\mathrm{m}}$ value presented in this work was averaged from two groups of parallel experiments. The mean residue ellipticity (MRE, $[\theta]$ ) was determined using the equation $[\theta]=(\theta \times m) /(c \times l \times n)[\theta$ : measured ellipticity (mdeg); $n$ : the number of amino acid residues in the peptide; $m$ : the molecular weight $(\mathrm{g} / \mathrm{mol})$; $c$ : the concentration ( $\mathrm{mg} / \mathrm{mL}$ ); $l$ : the path length of the cuvette $(\mathrm{mm})$ ].

## B-factors calculations

To allow comparison among different PDB structures, the normlized B-factors (Figure S4-5) of each CMP triplehelix structure we found in PDB (Figure S2) were calculated by dividing the B-factor of each non-hydrogen atom by the mean B-factor value of all non-hydrogen, non-water atoms within the whole triple-helix. To further reflect the deviation of the B -factors at the N - and C -termini of each peptide chain, we assessed the standard deviation (designated as $\sigma$ ) of the normalized atomic B-factors of the N -terminal most (Figure S3) and the C-terminal most amino acid triplet (Figure 3b) using the equation:

$$
\sigma=\sqrt{\frac{1}{N} \sum_{i=1}^{N}\left(B_{i}-1\right)^{2}}
$$

where $N$ is the number of totally non-hydrogen peptide atoms in the terminal unit of interest, $B_{i}$ is the value of the normalized B-factor of a given non-hydrogen atom within the terminal unit, and 1 represents the nomalized mean B-factor value of the whole triple-helix.

## Fully atomistic molecular dynamics (MD) of collagen sequences

We started by using the fully equilibrated tropocollagen structure of (GPO) ${ }_{10}$ as the template, we used psfgen, as a tool of NAMD package ${ }^{2}$ to remove certain amount of residues from the N - and C -terminus, and added acetylated N -terminus (Ac-) and amidated C-terminus $\left(-\mathrm{NH}_{2}\right)$ and methylated C-terminus $\left(-\mathrm{OCH}_{3}\right)$ to each of the collagen chains to obtain the initial molecular structure corresponding to the sequence $\mathrm{Ac}-(\mathrm{GPO})_{7}-\mathrm{NH}_{2}, \mathrm{Ac}-(\mathrm{GPO})_{7} \mathrm{G}-\mathrm{NH}_{2}$, $\mathrm{Ac}-(\mathrm{POG})_{7}-\mathrm{NH}_{2}, \mathrm{Ac}-(\mathrm{GPO})_{7}-\mathrm{OCH}_{3}$ as in this study. Classical fully atomistic molecular dynamics (MD) simulations were used to fully equilibrate the collagen in the explicit water box with dimension of $10.5 \times 5 \times 5 \mathrm{~nm}^{3}$ composed of 100 mM NaCl and TIP3P water molecules ${ }^{3}$. Simulation was carried with a CHARMM27 all atom energy force field ${ }^{3}$. The net charge of the system was zero by adjusting the ratio between cation and anion and each ion was initially distributed randomly in water with at least $5 \AA$ from the collagen structure. The simulation time step was 2 fs with rigid bonds model for all the covalent bonds between hydrogen atoms and other heavy atoms. We use particle mesh Ewald (PME) function with a grid width <1 Å to calculate the electronic interaction as an efficient method to accurately include all the long-distance electrostatics interactions. For the initial run, each of all the backbone atoms was constrained in space by elastic springs with the stiffness of $5 \mathrm{kcal} / \mathrm{mol} / \AA^{2}$ in all the 3 directions, while the side chain atoms and solvent molecules were free to move. We ran 10,000 steps of energy minimization by using a conjugate gradient and line search algorithm followed by 2 ns dynamics run for initial equilibrium. The dynamics simulation was performed in the NPT (constant pressure of 1 atm and constant temperature of 310 K ) ensemble controlled by the Langevin dynamics to reach a constant pressure and temperature (with $5 \mathrm{ps}^{-1}$ damping coefficient for temperature, 100 fs oscillation period and 50 fs damping time scale for pressure control) with the shrinkable volume during the run. After the initial run, we restarted the simulation, released all the constraints on the backbone
atoms and continue using NPT ensemble for 20 ns in the purpose of getting fully equilibrated collagen structures. The simulations were performed by using a NAMD package (v2.12) ${ }^{2}$ in the local Linux workstation with multiple graphics processing units (NVIDIA RTX 3060) support through Compute Unified Device Architecture (CUDA v11.4).

## Post analysis of simulation results

Visual Molecular Dynamics (VMD) was used for post-processing of the MD simulation results. It was used to visualize and analyze molecular structures by going through each frame of the simulation trajectory ( 2 ps per frame, 10,000 frames in total) that include the double-precision coordinate of each atom. We developed our TCL scripts in VMD to calculate the number of hydrogen bonds between any two residues I and $\mathbf{J}$ (given by $\mathrm{H}_{\mathrm{II}}$, as illustrated by each pixel in Fig. 4a). By going through all the atom pairs eligible to be donor/acceptor, a hydrogen bond was added to $\mathrm{H}_{\mathrm{IJ}}$ if the donor-acceptor distance is smaller than $3.5 \AA$ and the donor-hydrogen-acceptor angle is smaller than $35^{\circ}$. We computed the time-average value of this matrix $\overline{\mathrm{H}_{\mathrm{IJ}}}$ and plot it by heat maps (Fig. 4a by using MATLAB. We removed the overall rigid-body movement of the collagen by aligning all the frames against the geometry of the collagen after the initial run. To understand the effect of collagen sequence on the dynamics of the molecule at different regions, we focused on three regions including 9 residues at the N -terminal (residue $1-3$ for each of the three chains), 9 residues at middle (residue 10-12 for each of the three chains) and 9 residues at C terminal (residue 20-22 for each of the three chains in CMP 3, residue 19-21 in other sequences). We computed the root-mean-square deviation (RMSD) and the radius of gyration $\left(R_{g}\right)$ for each of these three regions in each frame (every 2 ps during the simulation, raw data as plotted in Fig. S6 and Fig. S7). We computed the time-average and standard deviation value of RMSD and $\mathrm{R}_{\mathrm{g}}$ during the 20 ns relaxation process, as shown by the bar plots in Fig. 4b. We ran two-sample t-test for RMSD and $\mathrm{R}_{\mathrm{g}}$ between $\mathrm{Ac}-(\mathrm{GPO})_{7}-\mathrm{NH}_{2}$ and other sequences. Since t -test on large sample size almost always lead to an extremely small p-value once the mean was slightly different, we chose to compute the mean value of RMSD and $\mathrm{R}_{\mathrm{g}}$ for every 200 ps , and use $\mathrm{N}=100$ per group to perform the t -test and compute the $p$-value, as given by the stars in Fig. 4 b .

## Differential scanning calorimetry (DSC)

All DSC studies were carried out using a MicroCal VP-DS Micro Calorimeter with the parameters (heating range: $20-70^{\circ} \mathrm{C}$, scan rate $2{ }^{\circ} \mathrm{C} / \mathrm{min}$, feedback set to "none" for enhanced signal-to-noise ratio). ${ }^{4,5}$ All CMP samples were heated at $85^{\circ} \mathrm{C}$ for 10 min and incubated at $4^{\circ} \mathrm{C}$ for at least 48 hours before measurement to allow full triple-helix assembly. Each peptide solution ( $250 \mu \mathrm{M}$ in PBS) were centrifuged at $12,000 \mathrm{rpm}$ for 10 minutes at $4^{\circ} \mathrm{C}$ before testing, and the supernatant was added to the sample cell. Measurements were repeated three times on three identical samples and averaged for each peptide. For data analysis, the DSC curve in PBS buffer was used as the baseline and subtracted from each peptide curve. The heat capacity ( $C$ p) baseline was also subtracted. The melting
temperature of the system was defined as the temperature at which the maximum measured $C$ p was observed. The enthalpy change $(\Delta H)$ for this process was measured as the calorimetric area under each DSC unfolding curve. The non-two state fitting method was used to fit the data.

## Gelatin binding assays

Carboxyfluorescein-labeled CMP 1F [CF-Ahx-(POG) $)_{7}-\mathrm{NH}_{2}$ ], CMP 2F [CF-Ahx-(GPO) $)_{7}$ - $\mathrm{NH}_{2}$ ] and CMP 4F [CF-Ahx-(OGP $)_{7}-\mathrm{NH}_{2}$ ] were prepared by reacting the N -terminal amines of the sequences on-resin with 6 molar equivalents of 5(6)-carboxyfluorescein activated by 6 molar equivalents of PyAOP with 12 molar equivalents of DIEA in NMP for over 48 hours before the resins were treated with $20 \%$ piperidine (in DMF) for 30 min. The CFCMPs were cleaved from the resin, purified by HPLC with protection from ambient light, and verified by MALDIMS (calculated mass: $2381.0[\mathrm{M}+\mathrm{Na}]^{+}$for the three CMPs; CMP 2F, observed: $2380.0[\mathrm{M}+\mathrm{Na}]^{+}$; CMP 1F, observed: $2379.9[\mathrm{M}+\mathrm{Na}]^{+} ; \mathrm{CMP}$ 4F, observed: $2381.0[\mathrm{M}+\mathrm{Na}]^{+}$).

The wells of a 96-well plate (Nunc, 468667-1) were coated with $50 \mu \mathrm{~L}$ of gelatin solution ( $100 \mu \mathrm{~g} / \mathrm{mL}$, SigmaAldrich, V900863-100G) in $1 \times$ PBS and incubated at $4{ }^{\circ} \mathrm{C}$ overnight. The wells were rinsed with $250 \mu \mathrm{~L}$ of $25^{\circ} \mathrm{C}$ $1 \times$ PBS six times. PBS solution $(100 \mu \mathrm{~L})$ containing $15 \mu \mathrm{M}$ of $\mathrm{CMP} \mathbf{1 F}, \mathbf{2 F}$ or $\mathbf{4 F}$ was heated at $80^{\circ} \mathrm{C}$ for 10 min and cooled in ice-water bath for 15 s before being immediately added to each well to allow binding with the coated gelatin for 4 hours at $4{ }^{\circ} \mathrm{C}$. After washing 6 times with $1 \times \mathrm{PBS}$, the fluorescence intensity of each well was measured on a Synergy HTX multi-mode reader (Ex: 485 nm, Em: 528 nm, Gain: 80).

## Immunofluorescence staining

Paraffin-embedded sections of hearts from normal SD rats (purchased from UptBio) were deparaffinized, washed with PBS and blocked with 5\% goat serum according to standard procedures. ${ }^{7}$ Antigen-retrieval process were performed by heating the slides at $110^{\circ} \mathrm{C}$ in sodium citrate buffer in a pressure cooker for 10 min . PBS solution $(100 \mu \mathrm{~L})$ containing $15 \mu \mathrm{M}$ of $\mathrm{CMP} \mathbf{1 F}, \mathbf{2 F}$ or $\mathbf{4 F}$ was heated at $85^{\circ} \mathrm{C}$ for 10 min and cooled in ice-water bath for 15 s before being immediately added to the tissue slides. The slides were incubated with the CMP solutions at $4{ }^{\circ} \mathrm{C}$ overnight. ${ }^{8}$ After staining with DAPI followed by three rounds of PBS wash, the slides were mounted for imaging (EVOS M7000 imaging system, Thermo Fisher). In another experiment, $85^{\circ} \mathrm{C}$-heated CMP 2 F solution ( $15 \mu \mathrm{M}$ in PBS) was immediatedly cooled on ice for 15 s before an anti-collagen I antibody (Abcam ab24821; 1:300) was diluted into it. The slides were co-stained by this mixture of CMP 2F and the collagen I antibody as described above. The primary antibody was detected with a AF647-labeled secondary antibody (Abcam ab150079; 1:200), washed thoroughly with PBS, and mounted for imaging.

## Section 2：Supplementary Tables and Figures

Table S1．Terminal（boundary）sequences of the recognized triple－helix regions in different types of human collagen $\alpha$－chains in UniProt．All terminal sequences featuring non－GXY repeats were shaded in grey．
＊Multiple terminal repeats were shown for chains with multiple triple－helix regions．

| Human collagen type \＆ chain |  | UniProt ID | Sequence of the triple－helix domain |  |
| :---: | :---: | :---: | :---: | :---: |
|  |  | N －terminal most 9 amino acids | C－terminal most 9 amino acids |
| I | 人1 |  | P02452 | GPMGPSGPR | GPPGPPGPP |
| II | $\alpha 1$ | P02458 | GPMGPMGPR | GPPGPPGPP |
| III | 人1 | P02461 | GLAGYPGPA | GPPGAPGPC |
| IV | 人1 | P02462 | GERGFPGIP | PPGPDGLPG |
|  | 人2 | P08572 | GEPGEPGLV | PGLPGMPGR |
|  | 人3 | Q01955 | GAKGEKGEK | GKRGDSGSP |
|  | $\alpha 4$ | P53420 | GPPGPPGPQ | GDPGPKGFG |
| V | 人1 | P20908 | GPAGPMGLT | PPGPPGPPG |
|  | 人3 | P25940 | GPPGAPGPQ | GPPGPPGAP |
| VI | 人1 | P12109 | GPPGLRGDP | GHQGPPGPD |
|  | 人2 | P12110 | PSGPKGYRG | GPPGDPGLT |
|  | 人3 | P12111 | QRGDRGPIG | KGNRGDSID |
| VII | $\alpha 1$ | Q02388 | GQKGEPGEM | PRGEKGEAA |
| VIII | 人1 | P27658 | GEQGPRGEP | GPPGPPGPP |
|  | 人2 | P25067 | GEPGPPGKP | GPPGAPGAF |
| IX | 人1 | P20849 | GATGLPGRP | GPPGLPGFC |
|  | $\alpha 2$ | Q14055＊ | GKDGDRGSP／GAVGMMGPP／GMKGPPGLQ／ GPPGERGPP | GPVGLPGFC／GLPGRPGQA／ GRQGVEGRDGKPGRPGTI |
|  | 人3 | Q14050＊ | GQDGAPGEP／GSIGRPGPA／GLPGPPGPP | IGAQGTPGI／GPQGVPGTS／ GKPGVPGKE |
| X | $\alpha 1$ | Q03692 | GEQGTPGPP | GPPGPPGQA |
| XI | 人1 | P12107 | GPPGPMGLT | GSPGPPGEV |
|  | $\alpha 2$ | P13942 | GPPGPMGYT | GHPGPPGEV |
| XII | 人1 | Q99715＊ | GPPGPPGPP／GPPGPPGPA | GPPGPPGYC／GEKGDRGDI |
| XIII | $\alpha 1$ | Q5TAT6＊ | GPPGPTGRP／GPPGPPGPP／GPPGLPGQI | GEKGQCGEY／GSKGEPGKG／ GDQGAPGLD |
| XIV | $\alpha 1$ | Q05707＊ | VALGPAGPP／GPPGEPGRP | GERGERGDL／APHPDQPEF |
| XV | $\alpha 1$ | P39059＊ | GVKGEKGDR／GPPGEKGSW／GLKGLPGNP | GAQGPPGPP / GPPGPPGPP / GPRGPPGHI |
| XVII | $\alpha 1$ | Q9UMD9 | GSPGPKGDM | GEKGDKGDQ |
| XVIII | $\alpha 1$ | P39060＊ | GPPGPPGPP／GEKGDRGDA | GPPGPPGPPGPP／ERGEPGGGG |
| XIX | $\alpha 1$ | Q14993＊ | GPPGPKGEK／GRPGPPGKD／QASVPGLKS | GPPGPPGPP／GLPGSPGAP／ GPPGPPGIP |
| XXVII | 人1 | Q8IZC6 | GPPGPKGDC | GRPGPPGPP |

Table S2. The sequences and $T_{\mathrm{m}}$ values of all CMPs in this study ( O : hydroxyproline, Ac: acetyl, $\mathrm{NH}_{2}$ : amide, OH : carboxyl, $\mathrm{OCH}_{3}$ : methyl ester, Sar: sarcosine).

| Acronym in main text | Sequence | $\begin{aligned} & T_{\mathrm{m}}\left({ }^{\circ} \mathrm{C}\right) \\ & \text { in PBS } \end{aligned}$ |
| :---: | :---: | :---: |
|  | $\mathrm{Ac}-(\mathrm{POG})_{5}-\mathrm{NH}_{2}$ | -- |
|  | $\mathrm{Ac}-(\mathrm{POG})_{6}-\mathrm{NH}_{2}$ | 30 |
| CMP 1 | $\mathrm{Ac}-(\mathrm{POG})_{7}-\mathrm{NH}_{2}$ | 45 |
|  | H -(POG) $)_{7}-\mathrm{NH}_{2}$ | 37 |
|  | $\mathrm{Ac}-(\mathrm{POG})_{7}$ - OH | 42 |
|  | Ac -(POG) $)_{8} \mathrm{NH}_{2}$ | 56 |
|  | Ac -(POG)9, $\mathrm{NH}_{2}$ | 65 |
|  | Ac -(GPO) $)_{5}-\mathrm{NH}_{2}$ | 23 |
|  | Ac -(GPO) $)_{6}-\mathrm{NH}_{2}$ | 42 |
| CMP 2 | $\mathrm{Ac}-(\mathrm{GPO})_{7}-\mathrm{NH}_{2}$ | 55 |
|  | H -(GPO) $)_{7}-\mathrm{NH}_{2}$ | 49 |
| CMP 20 | Ac (-(GPO) ${ }_{7}$ - OH | 36 |
| CMP 2E | $\mathrm{Ac}-(\mathrm{GPO})_{7}-\mathrm{OCH}_{3}$ | 44 |
|  | Ac -(GPO) $)_{8}-\mathrm{NH}_{2}$ | 64 |
|  | Ac -(GPO)9- $\mathrm{NH}_{2}$ | 72 |
| CMP 3 | $\mathrm{Ac}-\mathrm{G}(\mathrm{POG})_{7}-\mathrm{NH}_{2}=\mathrm{Ac}$-(GPO) $)_{7} \mathrm{G}-\mathrm{NH}_{2}$ | 47 |
| CMP 3A | $\mathrm{H}-\mathrm{G}(\mathrm{POG})_{7}-\mathrm{NH}_{2}=\mathrm{H}-(\mathrm{GPO})_{7} \mathrm{G}-\mathrm{NH}_{2}$ | 42 |
| CMP 3S ${ }_{\text {N }}$ | $\mathrm{Ac}-\mathrm{Sar}(\mathrm{POG})_{7}-\mathrm{NH}_{2}$ | 41 |
| CMP 3S ${ }_{\text {c }}$ | Ac -(GPO) $)_{7} \mathrm{Sar}-\mathrm{NH}_{2}$ | 42 |
| CMP 4 | Ac -(OGP) $)_{7}-\mathrm{NH}_{2}$ | 44 |
|  | H -(OGP) $)_{7}-\mathrm{NH}_{2}$ | 43 |
|  | Ac -(OGP) 7 - OH | 36 |
|  | Ac -(OGP) $)_{8}-\mathrm{NH}_{2}$ | 56 |
| CMP 5 | $\mathrm{Ac}-\mathrm{P}(\mathrm{OGP})_{7}-\mathrm{NH}_{2}=\mathrm{Ac}-(\mathrm{POG})_{7} \mathrm{P}-\mathrm{NH}_{2}$ | 52 |
| CMP 6 | $\mathrm{Ac}-\mathrm{O}(\mathrm{GPO})_{7}-\mathrm{NH}_{2}=\mathrm{Ac}-(\mathrm{OGP})_{7} \mathrm{O}-\mathrm{NH}_{2}$ | 56 |
|  | $\mathrm{Ac}-\mathrm{GP}(\mathrm{OGP})_{7}-\mathrm{NH}_{2}=\mathrm{Ac}-(\mathrm{GPO})_{7} \mathrm{GP}-\mathrm{NH}_{2}$ | 54 |
|  | $\mathrm{Ac}-\mathrm{PO}(\mathrm{GPO})_{7}-\mathrm{NH}_{2}=\mathrm{Ac}-(\mathrm{POG})_{7} \mathrm{PO}-\mathrm{NH}_{2}$ | 62 |
|  | $\mathrm{Ac}-\mathrm{OG}(\mathrm{POG})_{7}-\mathrm{NH}_{2}=\mathrm{Ac}-(\mathrm{OGP})_{7} \mathrm{OG}-\mathrm{NH}_{2}$ | 48 |

Table S3. Analysis crystal structure of reported CMP triple-helices in PDB. Note that more unresolved or missing terminal residues are found in the POG-repeating sequences.

| $\begin{gathered} \text { PDB } \\ \text { ID } \end{gathered}$ | N-end group | Sequence | C-end group | Unresolved terminal residues |  | $\begin{gathered} \text { Distance \& angle } \\ \text { for the possible C- } \\ \text { end most (Pro) } \\ \mathrm{C}=\mathrm{O} \ldots \mathrm{NH}(\mathrm{Gly} / \mathrm{H}) \\ \mathrm{H} \text {-bonds } \end{gathered}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  |  |  | N-end | C-end |  |
| 5K86 | H | $(\mathrm{POG})_{3} \mathrm{PRX}_{\text {za }}(\mathrm{POG})_{4}$ | $\mathrm{NH}_{2}$ | - | - | $\begin{aligned} & 2.8\left(172.9^{\circ}\right) \\ & 2.8\left(159.7^{\circ}\right) \end{aligned}$ |
| 4Z1R | H | $(\mathrm{POG})_{4} \mathrm{POA}(\mathrm{POG})_{5}$ | $\mathrm{NH}_{2}$ | B chain: Pro \& Hyp; C chain: Pro \& Hyp | A chain: Pro, Hyp\&Gly; <br> B chain: Hyp \& Gly; <br> C chain: Pro, Hyp\&Gly | 2.9 (156.3 ${ }^{\circ}$ ) |
| 3WN8 | H | $(\mathrm{POG})_{3} \mathrm{PRG}(\mathrm{POG})_{4}$ | OH | - | B chain: Gly | $\begin{aligned} & 2.8\left(153.5^{\circ}\right) \\ & 2.8\left(173.9^{\circ}\right) \end{aligned}$ |
| 2DRX | H | $(\mathrm{POG})_{4} \mathrm{LOGLOG}(\mathrm{POG})_{4}$ | OH | B chain: Pro | A chain: Hyp \& Gly; | $\begin{aligned} & 3.2\left(160.0^{\circ}\right) \\ & 3.0\left(142.6^{\circ}\right) \end{aligned}$ |
| 2DRT | H | (POG)4LOG(POG) ${ }_{5}$ | OH | A chain: Pro; B chain: Pro | C chain: Hyp \& Gly | $\begin{aligned} & 2.6\left(161.3^{\circ}\right) \\ & 2.6\left(149.5^{\circ}\right) \\ & \hline \end{aligned}$ |
| 1CAG | H | $(\mathrm{POG})_{4} \mathrm{POA}(\mathrm{POG})_{5}$ | OH | - | A chain: Gly; C chain: Gly | 2.5 (122.7 ${ }^{\circ}$ ) |
| 1BKV | H | (POG) ${ }_{3}$ ITGARGLAG(POG) 4 | OH | A chain: Pro | - | 2.9 (153.8 ${ }^{\circ}$ ) |
| 1CGD | H | $(\mathrm{POG})_{4} \mathrm{POA}(\mathrm{POG})_{5}$ | OH | - | - | $\begin{gathered} \hline 3.1(174.3) \\ 2.6\left(160.9^{\circ}\right) \\ \hline \end{gathered}$ |
| 3POD | Ac | $(\mathrm{GPO})_{3} \mathrm{GKL}(\mathrm{GPO})_{4}$ | $\mathrm{NH}_{2}$ | - | - | $\begin{aligned} & 2.7\left(159.5^{\circ}\right) \\ & 2.8\left(160.6^{\circ}\right) \\ & 2.9\left(165.8^{\circ}\right) \end{aligned}$ |
| 3PON | Ac | $(\mathrm{GPO})_{4} \mathrm{GKL}(\mathrm{GPO})_{4}$ | $\mathrm{NH}_{2}$ | - | C chain: Pro \& Hyp | $\begin{aligned} & 2.9\left(162.3^{\circ}\right) \\ & 3.0\left(161.3^{\circ}\right) \end{aligned}$ |
| 7JX4 | Ac | $(\mathrm{GPO})_{3} \mathrm{G}-\mathrm{NLys}-\mathrm{O}(\mathrm{GPO})_{3}$ | $\mathrm{NH}_{2}$ | - | - | $\begin{gathered} \hline 2.8\left(95.1^{\circ}\right) \\ 2.9\left(86.1^{\circ}\right) \\ 2.9\left(162.8^{\circ}\right) \\ \hline \end{gathered}$ |
| 7JX5 | Ac | $(\mathrm{GPO})_{3} \mathrm{G}-\mathrm{NPhe-O}(\mathrm{GPO})_{3}$ | $\mathrm{NH}_{2}$ | - | - | - |
| 1Q7D | Ac | $(\mathrm{GPO})_{2} \mathrm{GFOGER}(\mathrm{GPO})_{3}$ | $\mathrm{NH}_{2}$ | - | C chain: Hyp | $\begin{aligned} & \hline 2.7 \text { (160.3) } \\ & 2.7 \text { (146.2) } \\ & \hline \end{aligned}$ |
| 4DMT | Ac | $(\mathrm{GPO})_{3} \mathrm{GPRGQOGVMGFO}($ $\mathrm{GPO})_{3}$ <br> $\mathrm{GPO}_{3}$ | $\mathrm{NH}_{2}$ | A chain: Ac | - | $\begin{aligned} & 2.9\left(163.1^{\circ}\right) \\ & 2.9\left(153.7^{\circ}\right) \\ & 2.8(165.3) \\ & \hline \end{aligned}$ |
| 3P46 | Ac | $(\mathrm{GPO})_{2} \mathrm{GLOGEA}(\mathrm{GPO})_{2}$ | $\mathrm{NH}_{2}$ | C chain: Ac | - | $\begin{aligned} & 3.0\left(144.3^{\circ}\right) \\ & 2.6\left(160.2^{\circ}\right) \\ & \hline \end{aligned}$ |

Table S4. Comparison between various $T_{\mathrm{m}}$ values of similar CMPs from this study and previous reports.

| CMP | Source | $\begin{gathered} \boldsymbol{T}_{\mathrm{m}} \\ \left({ }^{\circ} \mathbf{C}\right) \end{gathered}$ | N-end | Sequence | C-end | Heating rate ( ${ }^{\circ} \mathrm{C} / \mathrm{min}$ ) | Notes |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| (POG)8 | This work | 56 | Ac- | (POG) 8 | $-\mathrm{NH}_{2}$ | 0.5 | The decreased $T_{\mathrm{m}}$ value compared to our work is most likely due to the slower heating rate. |
|  | Ref. 25 | 50.5 | Ac- | (POG) 8 | $-\mathrm{NH}_{2}$ | 0.1 |  |
|  | $T_{\mathrm{m}}$ estimation considering each factor | 50 | 0 | 0 | 0 | -6 |  |
|  |  |  | estimated $\Delta T_{\mathrm{m}}\left({ }^{\circ} \mathrm{C}\right)$ comparing to our work |  |  |  |  |
| (POG) ${ }_{10}$ | This work | 65 | Ac- | (POG)9 | $-\mathrm{NH}_{2}$ | 0.5 | The decreased $T_{\mathrm{m}}$ value compared to our work is likely due to the slower heating rate and charge repulsions between the uncapped Cand N -termini. |
|  | Ref. 56 Biopolymers. 2011;96(1):4-13. | 57 | $\mathrm{NH}_{2}-$ | $(\mathrm{POG})_{10}$ | - COOH | 0.1 |  |
|  | $T_{\mathrm{m}}$ estimation considering each factor | 56 | -8 | +8 | -3 | -6 |  |
|  |  |  | estimated $\Delta T_{\mathrm{m}}\left({ }^{\circ} \mathrm{C}\right)$ comparing to our work |  |  |  |  |
| (GPO) ${ }_{8}$ | This work | 64 | Ac- | $(\mathrm{GPO})_{8}$ | $-\mathrm{NH}_{2}$ | 0.5 | Besides the factor of the slower CD heating rates, the decrease in $T_{\mathrm{m}}$ value comparing to our study is probably due to the influence of Cterminal GlyGly which should disrupt the terminal H -bonding, according to our study. |
|  | Ref. 19 | 47.3 | Ac- | (GPO) ${ }_{8} \mathrm{GG}$ | $-\mathrm{NH}_{2}$ | 0.1 |  |
|  | Ref. 26 | 44.5 | Ac- | (GPO) ${ }_{8} \mathrm{GG}$ | $-\mathrm{NH}_{2}$ | $<0.1$ |  |
|  | $T_{\mathrm{m}}$ estimation considering each factor | < 50 | 0 | $<-8$ | 0 | -6 |  |
|  |  |  | estimated $\Delta T_{\mathrm{m}}\left({ }^{\circ} \mathrm{C}\right)$ comparing to our work |  |  |  |  |



Figure S1. The $T_{\mathrm{m}}$ values of $\mathrm{Ac}-(\mathrm{GPO})_{7}-\mathrm{NH}_{2}$ measured under various heating rates (peptide concentration: $150 \mu \mathrm{M}$; buffer: PBS; CD wavelength: 225 nm ; data interval: $0.1^{\circ} \mathrm{C}$; bandwidth: 5 nm ; digital integration time: 16 s , temperature range: 4 to $80^{\circ} \mathrm{C}$ ).
a


Ac-(POG) ${ }_{n}-\mathrm{NH}_{2}, \mathrm{n}: 5 \rightarrow 9$
b


Ac-(GPO) $)_{n}-\mathrm{NH}_{2}, \mathrm{n}: 5 \rightarrow 9$
C

| $=$ | $T_{\mathrm{m}}\left({ }^{\circ} \mathrm{C}\right)$ |  |  |
| :---: | :---: | :---: | :---: |
|  | $\mathrm{Ac}-(\mathrm{POG})_{\mathrm{n}}-\mathrm{NH}_{2}$ | Ac- $(\mathrm{GPO})_{\mathrm{n}}-\mathrm{NH}_{2}$ | $\Delta T_{\mathrm{m}}$ |
| 5 | -- | 23 | -- |
| 6 | 30 | 42 | 12 |
| 7 | 45 | 55 | 10 |
| 8 | 56 | 64 | 8 |
| 9 | 65 | 72 | 7 |

Figure S2. The $T_{\mathrm{m}}$ values of GPO-repeating CMPs are consistently higher than the POG-ones of equal numbers of repeats. a, Thermal denaturation curves of $\mathrm{Ac}-(\mathrm{POG})_{n}-\mathrm{NH}_{2}$ with n varying from 5 to 9 . Ac -(POG) $)_{-}-\mathrm{NH}_{2}$ does not form a triple-helix. $\mathbf{b}$, Thermal denaturation curves of Ac-(GPO) $\mathrm{n}_{\mathrm{n}}-\mathrm{NH}_{2}$ with n varying from 5 to 9 . $\mathbf{c}, T_{\mathrm{m}}$ values of the two CMP series with incremental numbers of repeats and the gradually decreasing $\Delta T_{\mathrm{m}}$ value.


Figure S3. Normalized B-factors for all non-hydrogen atoms of CMPs featuring the POG repeats.


Figure S4. Normalized B-factors for all non-hydrogen atoms of CMPs featuring GPO repeats.


Figure S5. The deviation of atomic B-factors of the N-terminal amino acid triplet (POG v.s. GPO) from the mean B-factor of all non-hydrogen atoms in a given triple-helix. Unlike the GPO CMPs, none of the N-terminal POG featuring CMPs we found in PDB were N-acetylated. Each * indicates one unresolved and missing N-terminal amino acid residue in the crystal structure.


Figure S6. The root-mean-square deviation (RMSD) values of four CMP triple-helices at the N- and C-termini, and the sequence center.
CMP 2: $\mathrm{Ac}-(\mathrm{GPO})_{7}-\mathrm{NH}_{2}$
CMP 3: Ac-(GPO) $)_{7} \mathrm{G}_{-} \mathrm{NH}_{2}$
CMP 1: Ac-(POG) $)_{-} \mathrm{NH}_{2}$
CMP 2E: Ac-(GPO) $)_{7}-\mathrm{OCH}_{3}$


Figure S7. The radius of gyration $\left(\mathrm{R}_{\mathrm{g}}\right)$ values of four CMP triple-helices at the N - and C-termini, and the sequence center.
CMP 2: $\mathrm{Ac}-(\mathrm{GPO})_{7}-\mathrm{NH}_{2}$
CMP 3: Ac-(GPO) $)_{7} \mathrm{G}_{-} \mathrm{NH}_{2}$
CMP 1: Ac-(POG) $)_{-} \mathrm{NH}_{2}$
CMP 2E: $\mathrm{Ac}-(\mathrm{GPO})_{7}-\mathrm{OCH}_{3}$


Figure S8. The experimental and fitting curves of the DSC thermograms.


Figure S9. $T_{\mathrm{m}}$ value changes for stepwise incorporation of Gly, Hyp, and Pro to the N - or C -terminus of $\mathrm{Ac}-(\mathrm{POG})_{7-}$ $\mathrm{NH}_{2}$.


Figure S10. $T_{\mathrm{m}}$ value changes for stepwise incorporation of Pro, Gly, and Hyp to the N - or C-terminus of Ac(OGP) $)_{7}-\mathrm{NH}_{2}$.


Figure S11. Micrographs of a paraffin-embedded section of normal rat heart tissue stained with CMP 2F and an anti-collagen I antibody (after heat-mediated antigen retrieval to purposefully denature the collagen content) showing strongly overlapping CMP and antibody signals. Scale bar: $100 \mu \mathrm{~m}$.


Figure S12. Distribution of $\varphi$ and $\psi$ angles of representitive animo acid residues in the MD simulated structural relaxation process for CMP 2 and 3, showing that Gly was more flexible than Hyp at the C-terminus. Each color refers to the residues in one single CMP chain (orange: chain 1 ; red: chain 2 ; blue: chain 3 ).
*The phi $(\varphi)$ angle for the N-terminal residue G1 is defined by Cy-N-C $\alpha-\mathrm{C}$, where Cy is the carbon atom of the acetyl group attached to residue G1; ** The psi ( $\psi$ ) angle for the C-terminal reisude O7 (CMP 2) or G8 (CMP 3) is defined by $\mathrm{N}-\mathrm{C} \alpha-\mathrm{C}-\mathrm{Nt}$, where Nt is the nitrogen atom of the amide group connecting to the last residue.

## Supplementary Section 3: MALDI and CD of all peptides

## CMP $1 \mathrm{Ac}-(\mathrm{POG})_{7}-\mathrm{NH}_{2}$


a

b


d

e

a, The HPLC chromatogram of purified peptide, $\mathrm{t}_{\mathrm{R}}=16.6 \mathrm{~min}$. The purity is $96 \%$.
b, MALDI-MS, calculated: $1951.9[\mathrm{M}+\mathrm{Na}]^{+}$, observed: $1951.9[\mathrm{M}+\mathrm{Na}]^{+}, 1968.5[\mathrm{M}+\mathrm{K}]^{+}$.
c, The CD spectrum in PBS buffer at $4{ }^{\circ} \mathrm{C}$.
d, The CD thermal melting curve in PBS buffer.
e, The first derivative of the melting curve, $T_{\mathrm{m}}=45^{\circ} \mathrm{C}$.

## CMP $2 \mathrm{Ac}-(\mathrm{GPO})_{7}-\mathrm{NH}_{2}$



b




a, The HPLC chromatogram of purified peptide, $\mathrm{t}_{\mathrm{R}}=16.7 \mathrm{~min}$. The purity is $99 \%$.
b, MALDI-MS, calculated: 1951.9 [M+Na] ${ }^{+}$, observed: 1952.1 [M+Na] ${ }^{+}, 1968.2[\mathrm{M}+\mathrm{K}]^{+}$.
c, The CD spectrum in PBS buffer at $4^{\circ} \mathrm{C}$.
d, The CD thermal melting curve in PBS buffer.
$\mathbf{e}$, The first derivative of the melting curve, $T_{\mathrm{m}}=55^{\circ} \mathrm{C}$.

## CMP 2 O Ac-(GPO) $)_{7}-\mathrm{OH}$



a
b



e

a, The HPLC chromatogram of purified peptide, $\mathrm{t}_{\mathrm{R}}=16.5 \mathrm{~min}$. The purity is $99 \%$.
b, MALDI-MS, calculated: 1952.9 [M+Na] ${ }^{+}$, observed: $1953.9[\mathrm{M}+\mathrm{Na}]^{+}$.
b, The CD spectrum in PBS buffer at $4{ }^{\circ} \mathrm{C}$.
c, The CD thermal melting curve in PBS buffer.
d, The first derivative of the melting curve, $T_{\mathrm{m}}=36^{\circ} \mathrm{C}$.

## CMP 2E Ac-(GPO) $)_{7}-\mathrm{OCH}_{3}$



a, The HPLC chromatogram of purified peptide, $\mathrm{t}_{\mathrm{R}}=17.8 \mathrm{~min}$. The purity is $98 \%$.
b, MALDI-MS, calculated: 1966.9 [M+Na] ${ }^{+}$, observed: $1967.6[\mathrm{M}+\mathrm{Na}]^{+}$.
c, The CD spectrum in PBS buffer at $4{ }^{\circ} \mathrm{C}$.
d, The CD thermal melting curve in PBS buffer.
e, The first derivative of the melting curve, $T_{\mathrm{m}}=44^{\circ} \mathrm{C}$.

## CMP $3 \mathrm{Ac}-\mathrm{G}(\mathrm{POG})_{7}-\mathrm{NH}_{2}=\mathrm{Ac}-(\mathrm{GPO})_{7} \mathrm{G}-\mathrm{NH}_{2}$


a

b




a, The HPLC chromatogram of purified peptide, $\mathrm{t}_{\mathrm{R}}=16.9 \mathrm{~min}$. The purity is $98 \%$.
b, MALDI-MS, calculated: 2008.9 [M+Na] ${ }^{+}$, observed: $2009.9[\mathrm{M}+\mathrm{Na}]^{+}$.
c, The CD spectrum in PBS buffer at $4^{\circ} \mathrm{C}$.
d, The CD thermal melting curve in PBS buffer.
e, The first derivative of the melting curve, $T_{\mathrm{m}}=47^{\circ} \mathrm{C}$.

## CMP 3A H-G(POG) $)_{7}-\mathrm{NH}_{2}=\mathrm{H}-(\mathrm{GPO})_{7} \mathrm{G}-\mathrm{NH}_{2}$



b



a, The HPLC chromatogram of purified peptide, $t_{R}=16.0 \mathrm{~min}$. The purity is $96 \%$.
b, MALDI-MS, calculated: $1944.9[\mathrm{M}+\mathrm{H}]^{+}$, observed: $1945.2[\mathrm{M}+\mathrm{H}]^{+}, 1967.7[\mathrm{M}+\mathrm{Na}]^{+}$.
c, The CD spectrum in PBS buffer at $4^{\circ} \mathrm{C}$.
d, The CD thermal melting curve in PBS buffer.
$\mathbf{e}$, The first derivative of the melting curve, $T_{\mathrm{m}}=42^{\circ} \mathrm{C}$.

## CMP 3S $\mathbf{N A}_{\mathbf{N}} \mathrm{Ac}-\mathrm{Sar}(\mathrm{POG})_{7}-\mathrm{NH}_{2}$



a
b



e

a, The HPLC chromatogram of purified peptide, $\mathrm{t}_{\mathrm{R}}=16.5 \mathrm{~min}$. The purity is $99 \%$.
b, MALDI-MS, calculated: 2022.9 [M+Na] ${ }^{+}$, observed: $2023.9[\mathrm{M}+\mathrm{Na}]^{+}$.
c, The CD spectrum in PBS buffer at $4{ }^{\circ} \mathrm{C}$.
d, The CD thermal melting curve in PBS buffer.
$\mathbf{e}$, The first derivative of the melting curve, $T_{\mathrm{m}}=41^{\circ} \mathrm{C}$.

## CMP 3S $\left.\mathbf{c h c}_{\mathbf{c}} \mathrm{CHPO}\right)_{7} \mathrm{Sar}-\mathrm{NH}_{2}$


b



e

a, The HPLC chromatogram of purified peptide, $\mathrm{t}_{\mathrm{R}}=17.1 \mathrm{~min}$. The purity is $97 \%$.
b, MALDI-MS, calculated: 2022.9 [M+Na] ${ }^{+}$, observed: 2021.4 [M+Na] ${ }^{+} 2037.4[\mathrm{M}+\mathrm{K}]^{+}$.
c, The CD spectrum in PBS buffer at $4{ }^{\circ} \mathrm{C}$.
d, The CD thermal melting curve in PBS buffer.
e, The first derivative of the melting curve, $T_{\mathrm{m}}=42^{\circ} \mathrm{C}$.

## CMP $4 \mathrm{Ac}-(\mathrm{OGP})_{7}-\mathrm{NH}_{2}$



a
b



e

a, The HPLC chromatogram of purified peptide, $\mathrm{t}_{\mathrm{R}}=16.5 \mathrm{~min}$. The purity is $99 \%$.
b, MALDI-MS, calculated: 1951.9 [M+Na] ${ }^{+}$, observed: $1952.1[\mathrm{M}+\mathrm{Na}]^{+}, 1970.3$ [M+Na] ${ }^{+}$.
c, The CD spectrum in PBS buffer at $4{ }^{\circ} \mathrm{C}$.
d, The CD thermal melting curve in PBS buffer.
e, The first derivative of the melting curve, $T_{\mathrm{m}}=44^{\circ} \mathrm{C}$.

## CMP $5 \mathrm{Ac}-\mathrm{P}(\mathrm{OGP})_{7}-\mathrm{NH}_{2}=\mathrm{Ac}-(\mathrm{POG})_{7} \mathrm{P}-\mathrm{NH}_{2}$



b



e

a, The HPLC chromatogram of purified peptide, $\mathrm{t}_{\mathrm{R}}=16.9 \mathrm{~min}$. The purity is $99 \%$.
b, MALDI-MS, calculated: 2048.9 [M+Na] ${ }^{+}$, observed: $2050.0[\mathrm{M}+\mathrm{Na}]^{+}$.
c, The CD spectrum in PBS buffer at $4{ }^{\circ} \mathrm{C}$.
d, The CD thermal melting curve in PBS buffer.
e, The first derivative of the melting curve, $T_{\mathrm{m}}=52^{\circ} \mathrm{C}$.

## CMP $6 \mathrm{Ac}-\mathrm{O}(\mathrm{GPO})_{7}-\mathrm{NH}_{2}=\mathrm{Ac}-(\mathrm{OGP})_{7} \mathrm{O}-\mathrm{NH}_{2}$



b



e

a, The HPLC chromatogram of purified peptide, $\mathrm{t}_{\mathrm{R}}=16.1 \mathrm{~min}$. The purity is $98 \%$.
b, MALDI-MS, calculated: 2064.9 [M+Na] ${ }^{+}$, observed: $2066.0[\mathrm{M}+\mathrm{Na}]^{+}$.
c, The CD spectrum in PBS buffer at $4^{\circ} \mathrm{C}$.
d, The CD thermal melting curve in PBS buffer.
e, The first derivative of the melting curve, $T_{\mathrm{m}}=56^{\circ} \mathrm{C}$.

## $\mathrm{Ac}-(\mathrm{POG})_{5}-\mathrm{NH}_{2}$



b



e

a, The HPLC chromatogram of purified peptide, $\mathrm{t}_{\mathrm{R}}=15.8 \mathrm{~min}$. The purity is $99 \%$.
b, MALDI-MS, calculated: 1417.7 [M+Na] ${ }^{+}$, observed: $1417.3[\mathrm{M}+\mathrm{Na}]^{+}, 1433.5[\mathrm{M}+\mathrm{K}]^{+}$.
c, The CD spectrum in PBS buffer at $4{ }^{\circ} \mathrm{C}$.
d, The CD thermal melting curve in PBS buffer.
$\mathbf{e}$, The first derivative of the melting curve, no $T_{\mathrm{m}}$.

## $\mathrm{Ac}-(\mathrm{POG})_{6}-\mathrm{NH}_{2}$



b



e

a, The HPLC chromatogram of purified peptide, $\mathrm{t}_{\mathrm{R}}=16.7 \mathrm{~min}$. The purity is $99 \%$.
b, MALDI-MS, calculated: $1684.8[\mathrm{M}+\mathrm{Na}]^{+}$, observed: $1684.1[\mathrm{M}+\mathrm{Na}]^{+}, 1700.1[\mathrm{M}+\mathrm{K}]^{+}$.
c, The CD spectrum in PBS buffer at $4{ }^{\circ} \mathrm{C}$.
d, The CD thermal melting curve in PBS buffer.
e, The first derivative of the melting curve, $T_{\mathrm{m}}=30^{\circ} \mathrm{C}$.

## $\mathrm{H}-(\mathrm{POG})_{7}-\mathrm{NH}_{2}$



b



e

a, The HPLC chromatogram of purified peptide, $\mathrm{t}_{\mathrm{R}}=15.9 \mathrm{~min}$. The purity is $99 \%$.
b, MALDI-MS, calculated: 1887.9 [M+H] ${ }^{+}$, observed: 1888.3 [M+H] ${ }^{+}, 1909.4[\mathrm{M}+\mathrm{Na}]^{+}, 1926.4[\mathrm{M}+\mathrm{K}]^{+}$.
c, The CD spectrum in PBS buffer at $4{ }^{\circ} \mathrm{C}$.
d, The CD thermal melting curve in PBS buffer (blue) and 3.5 mM NaOH solution ( pH 11.5 , red).
e, The first derivative of the melting curve, $T_{\mathrm{m}}=37^{\circ} \mathrm{C}\left(\mathrm{PBS}\right.$, blue) or $42^{\circ} \mathrm{C}(\mathrm{NaOH}$, red $)$.

## $\mathrm{Ac}-(\mathrm{POG})_{7}-\mathrm{OH}$



b



e

a, The HPLC chromatogram of purified peptide, $\mathrm{t}_{\mathrm{R}}=17.3 \mathrm{~min}$. The purity is $99 \%$.
b, MALDI-MS, calculated: 1952.9 [M+Na] ${ }^{+}$, observed: 1953.1 [M+Na] ${ }^{+}, 1969.2[\mathrm{M}+\mathrm{K}]^{+}$.
c, The CD spectrum in PBS buffer at $4{ }^{\circ} \mathrm{C}$.
d, The CD thermal melting curve in PBS buffer.
$\mathbf{e}$, The first derivative of the melting curve, $T_{\mathrm{m}}=42^{\circ} \mathrm{C}$.

## $\mathrm{Ac}-(\mathrm{POG})_{8}-\mathrm{NH}_{2}$



b

d
a, The HPLC chromatogram of purified peptide, $\mathrm{t}_{\mathrm{R}}=16.8 \mathrm{~min}$. The purity is $98 \%$.
b, MALDI-MS, calculated: $2219.0[\mathrm{M}+\mathrm{Na}]^{+}$, observed: $2220.0[\mathrm{M}+\mathrm{Na}]^{+}$.
c, The CD spectrum in PBS buffer at $4^{\circ} \mathrm{C}$.
d, The CD thermal melting curve in PBS buffer.
$\mathbf{e}$, The first derivative of the melting curve, $T_{\mathrm{m}}=56^{\circ} \mathrm{C}$.

## $\mathrm{Ac}-(\mathrm{POG})_{9}-\mathrm{NH}_{2}$



b



e

a, The HPLC chromatogram of purified peptide, $\mathrm{t}_{\mathrm{R}}=17.6 \mathrm{~min}$. The purity is $99 \%$.
b, MALDI-MS, calculated: 2486.1 [M+Na] ${ }^{+}$, observed: $2485.9[\mathrm{M}+\mathrm{Na}]^{+}, 2501.9[\mathrm{M}+\mathrm{K}]^{+}$.
c, The CD spectrum in PBS buffer at $4{ }^{\circ} \mathrm{C}$.
d, The CD thermal melting curve in PBS buffer.
$\mathbf{e}$, The first derivative of the melting curve, $T_{\mathrm{m}}=65^{\circ} \mathrm{C}$.

## $\mathrm{Ac}-(\mathrm{GPO})_{5}-\mathrm{NH}_{2}$



b



e

a, The HPLC chromatogram of purified peptide, $\mathrm{t}_{\mathrm{R}}=15.5 \mathrm{~min}$. The purity is $99 \%$.
b, MALDI-MS, calculated: 1417.7 [M+Na] ${ }^{+}$, observed: $1416.2[\mathrm{M}+\mathrm{Na}]^{+}, 1432.37$ [M+K] ${ }^{+}$.
c, The CD spectrum in PBS buffer at $4{ }^{\circ} \mathrm{C}$.
d, The CD thermal melting curve in PBS buffer.
e, The first derivative of the melting curve, $T_{\mathrm{m}}=23^{\circ} \mathrm{C}$.

## $\mathrm{Ac}-(\mathrm{GPO})_{6}-\mathrm{NH}_{2}$



b



e

a, The HPLC chromatogram of purified peptide, $\mathrm{t}_{\mathrm{R}}=15.7 \mathrm{~min}$. The purity is $99 \%$.
b, MALDI-MS, calculated: 1684.8 [M+Na] ${ }^{+}$, observed: 1683.7 [M+Na] ${ }^{+}, 1699.8[\mathrm{M}+\mathrm{K}]^{+}$.
c, The CD spectrum in PBS buffer at $4{ }^{\circ} \mathrm{C}$.
d, The CD thermal melting curve in PBS buffer.
e, The first derivative of the melting curve, $T_{\mathrm{m}}=42^{\circ} \mathrm{C}$.

## $\mathrm{H}-(\mathrm{GPO})_{7}-\mathrm{NH}_{2}$


a

b




a, The HPLC chromatogram of purified peptide, $\mathrm{t}_{\mathrm{R}}=16.4 \mathrm{~min}$. The purity is $99 \%$.
b, MALDI-MS, calculated: $1887.9[\mathrm{M}+\mathrm{H}]^{+}$, observed: $1888.1[\mathrm{M}+\mathrm{H}]^{+}, 1910.3[\mathrm{M}+\mathrm{Na}]^{+}$.
c, The CD spectrum in PBS buffer at $4^{\circ} \mathrm{C}$.
d, The CD thermal melting curve in PBS buffer (blue) and 3.5 mM NaOH solution ( pH 11.5 , red).
e, The first derivative of the melting curve, $T_{\mathrm{m}}=49^{\circ} \mathrm{C}\left(\mathrm{PBS}\right.$, blue) or $50^{\circ} \mathrm{C}(\mathrm{NaOH}$, red $)$.

## $\mathrm{Ac}-(\mathrm{GPO})_{8}-\mathrm{NH}_{2}$



b



e

a, The HPLC chromatogram of purified peptide, $\mathrm{t}_{\mathrm{R}}=16.5 \mathrm{~min}$. The purity is $96 \%$.
b, MALDI-MS, calculated: $2219.0[\mathrm{M}+\mathrm{Na}]^{+}$, observed: $2220.0[\mathrm{M}+\mathrm{Na}]^{+}$.
c, The CD spectrum in PBS buffer at $4{ }^{\circ} \mathrm{C}$.
d, The CD thermal melting curve in PBS buffer.
e, The first derivative of the melting curve, $T_{\mathrm{m}}=64^{\circ} \mathrm{C}$.

## $\mathrm{Ac}-(\mathrm{GPO})_{9}-\mathrm{NH}_{2}$


a

b



e

a, The HPLC chromatogram of purified peptide, $\mathrm{t}_{\mathrm{R}}=17.5 \mathrm{~min}$. The purity is $99 \%$.
b, MALDI-MS, calculated: 2486.1 [M+Na] ${ }^{+}$, observed: $2485.4[\mathrm{M}+\mathrm{Na}]^{+}, 2501.8[\mathrm{M}+\mathrm{K}]^{+}$.
c, The CD spectrum in PBS buffer at $4{ }^{\circ} \mathrm{C}$.
d, The CD thermal melting curve in PBS buffer.
e, The first derivative of the melting curve, $T_{\mathrm{m}}=72^{\circ} \mathrm{C}$.

## $\mathrm{H}-(\mathrm{OGP})_{7}-\mathrm{NH}_{2}$



a
b



e

a, The HPLC chromatogram of purified peptide, $\mathrm{t}_{\mathrm{R}}=16.4 \mathrm{~min}$. The purity is $99 \%$.
b, MALDI-MS, calculated: 1887.9 [M+H] ${ }^{+}$, observed: $1888.6[\mathrm{M}+\mathrm{H}]^{+}, 1910.2[\mathrm{M}+\mathrm{Na}]^{+}$.
c, The CD spectrum in PBS buffer at $4{ }^{\circ} \mathrm{C}$.
d, The CD thermal melting curve in PBS buffer (blue) and 3.5 mM NaOH solution ( pH 11.5 , red).
e, The first derivative of the melting curve, $T_{\mathrm{m}}=43^{\circ} \mathrm{C}\left(\mathrm{PBS}\right.$, blue) or $40^{\circ} \mathrm{C}(\mathrm{NaOH}$, red $)$.

## $\mathrm{Ac}-(\mathrm{OGP})_{7}-\mathrm{OH}$



b



e

a, The HPLC chromatogram of purified peptide, $\mathrm{t}_{\mathrm{R}}=17.4 \mathrm{~min}$. The purity is $97 \%$.
b, MALDI-MS, calculated: 1952.9 [M+H] ${ }^{+}$, observed: $1953.0[\mathrm{M}+\mathrm{Na}]^{+}$, 1975.03 [M+K] ${ }^{+}$.
c, The CD spectrum in PBS buffer at $4{ }^{\circ} \mathrm{C}$.
d, The CD thermal melting curve in PBS buffer.
e, The first derivative of the melting curve, $T_{\mathrm{m}}=36^{\circ} \mathrm{C}$.

## $\mathrm{Ac}-(\mathrm{OGP})_{8}-\mathrm{NH}_{2}$



b



e

a, The HPLC chromatogram of purified peptide, $\mathrm{t}_{\mathrm{R}}=16.6 \mathrm{~min}$. The purity is $97 \%$.
b, MALDI-MS, calculated: $2219.0[\mathrm{M}+\mathrm{Na}]^{+}$, observed: $2220.0[\mathrm{M}+\mathrm{Na}]^{+}$.
c, The CD spectrum in PBS buffer at $4^{\circ} \mathrm{C}$.
d, The CD thermal melting curve in PBS buffer.
e, The first derivative of the melting curve, $T_{\mathrm{m}}=56^{\circ} \mathrm{C}$.
$\mathrm{Ac}-\mathrm{GP}(\mathrm{OGP})_{7}-\mathrm{NH}_{2}=\mathrm{Ac}-(\mathrm{GPO})_{7} \mathrm{GP}-\mathrm{NH}_{2}$


b



e

a, The HPLC chromatogram of purified peptide, $\mathrm{t}_{\mathrm{R}}=17.3 \mathrm{~min}$. The purity is $96 \%$.
b, MALDI-MS, calculated: $2106.0[\mathrm{M}+\mathrm{Na}]^{+}$, observed: $2015.5[\mathrm{M}+\mathrm{Na}]^{+}, 2121.5[\mathrm{M}+\mathrm{K}]^{+}$.
c, The CD spectrum in PBS buffer at $4{ }^{\circ} \mathrm{C}$.
d, The CD thermal melting curve in PBS buffer.
e, The first derivative of the melting curve, $T_{\mathrm{m}}=54^{\circ} \mathrm{C}$.
$\mathrm{Ac}-\mathrm{PO}(\mathrm{GPO})_{7}-\mathrm{NH}_{2}=\mathrm{Ac}-(\mathrm{POG})_{7} \mathrm{PO}-\mathrm{NH}_{2}$

a

b



e

a, The HPLC chromatogram of purified peptide, $\mathrm{t}_{\mathrm{R}}=17.3 \mathrm{~min}$. The purity is $96 \%$.
b, MALDI-MS, calculated: $2162.0[\mathrm{M}+\mathrm{Na}]^{+}$, observed: $2163.0[\mathrm{M}+\mathrm{Na}]^{+}$.
c, The CD spectrum in PBS buffer at $4{ }^{\circ} \mathrm{C}$.
d, The CD thermal melting curve in PBS buffer.
$\mathbf{e}$, The first derivative of the melting curve, $T_{\mathrm{m}}=62^{\circ} \mathrm{C}$.

## $\mathrm{Ac}-\mathrm{OG}(\mathrm{POG})_{7}-\mathrm{NH}_{2}=\mathrm{Ac}-(\mathrm{OGP})_{7} \mathrm{OG}-\mathrm{NH}_{2}$



b



e

a, The HPLC chromatogram of purified peptide, $\mathrm{t}_{\mathrm{R}}=16.1 \mathrm{~min}$. The purity is $96 \%$.
b, MALDI-MS, calculated: $2122.0[\mathrm{M}+\mathrm{Na}]^{+}$, observed: $2123.0[\mathrm{M}+\mathrm{Na}]^{+}$.
c, The CD spectrum in PBS buffer at $4{ }^{\circ} \mathrm{C}$.
d, The CD thermal melting curve in PBS buffer.
$\mathbf{e}$, The first derivative of the melting curve, $T_{\mathrm{m}}=48^{\circ} \mathrm{C}$.

## References

(1) Kessler, J. L.; Kang, G.; Qin, Z.; Kang, H.; Whitby, F. G.; Cheatham, T. E., 3rd; Hill, C. P.; Li, Y.;Yu, S. M. Peptoid residues make diverse, hyperstable collagen triple-helices. J. Am. Chem. Soc. 2021, 143 (29), 1091010919.
(2) Nelson, M. T.; Humphrey, W.; Gursoy, A.; Dalke, A.; Kalé, L. V.; Skeel, R. D.;Schulten, K. NAMD: a parallel, object-oriented molecular dynamics program. Int J High Perform Comput Appl. 1996, 10 (4), 251-268.
(3) MacKerell, A. D.; Bashford, D.; Bellott, M.; Dunbrack, R. L.; Evanseck, J. D.; Field, M. J.; Fischer, S.; Gao, J.; Guo, H.; Ha, S.; Joseph-McCarthy, D.; Kuchnir, L.; Kuczera, K.; Lau, F. T.; Mattos, C.; Michnick, S.; Ngo, T.; Nguyen, D. T.; Prodhom, B.; Reiher, W. E.; Roux, B.; Schlenkrich, M.; Smith, J. C.; Stote, R.; Straub, J.; Watanabe, M.; Wiórkiewicz-Kuczera, J.; Yin, D.;Karplus, M. All-atom empirical potential for molecular modeling and dynamics studies of proteins. J Phys Chem B. 1998, 102 (18), 3586-3616.
(4) O’Leary, L. E. R.; Fallas, J. A.;Hartgerink, J. D. Positive and negative design leads to compositional control in AAB collagen heterotrimers. J. Am. Chem. Soc. 2011, 133 (14), 5432-5443.
(5) Shoulders, M. D.; Satyshur, K. A.; Forest, K. T.;Raines, R. T. Stereoelectronic and steric effects in side chains preorganize a protein main chain. Proc. Natl. Acad. Sci. U. S. A. 2010, 107 (2), 559-564.
(6) Bennink, L. L.; Li, Y.; Kim, B.; Shin, I. J.; San, B. H.; Zangari, M.; Yoon, D.;Yu, S. M. Visualizing collagen proteolysis by peptide hybridization: From 3D cell culture to in vivo imaging. Biomaterials 2018, 183, 67-76.
(7) Hwang, J.; Huang, Y.; Burwell, T. J.; Peterson, N. C.; Connor, J.; Weiss, S. J.; Yu, S. M.;Li, Y. In situ imaging of tissue remodeling with collagen hbridizing peptides. ACS Nano 2017, 11 (10), 9825-9835.
(8) Liu, L.; Huang, K.; Li, W.; Qiu, R.; Fang, Y.; Huang, Y.; Zhao, S.; Lv, H.; Zhang, K.; Shan, H.;Li, Y. Molecular imaging of collagen destruction of the spine. ACS Nano 2021, 15 (12), 19138-19149.

